Detalhe da pesquisa
1.
The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
J Pharmacol Sci
; 127(4): 456-61, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892328
2.
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Bioorg Med Chem
; 20(19): 5705-19, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22959556
3.
MEN4901/T-0128, a new camptothecin derivative-carboxymethyldextran conjugate, has potent antitumor activities in a panel of human tumor xenografts in nude mice.
Clin Cancer Res
; 11(4): 1650-7, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15746070
4.
The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice.
Eur J Pharmacol
; 723: 207-15, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24309217
5.
Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
J Pharmacol Sci
; 106(1): 121-7, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18187929